<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gastrointestinal endoscopy in patients with disorders of hemostasis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gastrointestinal endoscopy in patients with disorders of hemostasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gastrointestinal endoscopy in patients with disorders of hemostasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick S Kamath, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with abnormal hemostasis may require gastrointestinal endoscopy and therapeutic interventions. However, data assessing the bleeding risk of specific procedures for such patients are limited.</p><p>This topic will provide an overview of periprocedural management for patients with an inherited or acquired disorder of hemostasis (eg, von Willebrand disease, hemophilia A or B, thrombocytopenia).</p><p>Diagnostic testing for specific platelet and coagulation factor disorders and overviews of the hemostatic process are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>Overview of the hemostatic process (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Overview of coagulation tests (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet disorders (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a> and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation factor deficiencies (See  <a class="medical medical_review" href="/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a> and  <a class="medical medical_review" href="/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a> and  <a class="medical medical_review" href="/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>von Willebrand disease (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinogen disorders (See  <a class="medical medical_review" href="/d/html/1321.html" rel="external">"Disorders of fibrinogen"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal fibrinolysis (See  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis"</a>.)</p><p></p><p>The periprocedural management for endoscopic procedures for patients taking anticoagulants or antiplatelet agents is discussed separately. (See  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a>.)</p><p class="headingAnchor" id="H3880252525"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H2223178376"><span class="h2">Factors that guide decision-making</span><span class="headingEndMark"> — </span>The management of patients with disorders of hemostasis who are undergoing endoscopy takes into consideration the severity of the patient's disease, the procedure-related bleeding risk, and the timing of the procedure (eg, urgent, elective). The bleeding risk also depends on the patient's underlying disorder and the availability of interventions to enhance hemostasis (eg, factor replacement for hemophilia, platelet transfusions for thrombocytopenia). In addition, routine laboratory testing (eg, platelet count, coagulation studies) may correlate with disease severity and bleeding risk; however, for some patients, routine testing does not reflect bleeding risk.</p><p>Much of our approach is based on expert opinion; bleeding risks may vary depending on individual circumstances, and data from randomized trials or well-designed observational studies are not available to guide clinical practice in all settings. Thus, this approach is intended as clinical guidance and does not substitute for clinical judgment in decisions about managing disorders of hemostasis.</p><p class="headingAnchor" id="H4044682778"><span class="h2">Estimating procedure-related bleeding risk</span><span class="headingEndMark"> — </span>The risk of bleeding depends on the endoscopic procedure and the need for (and type of) therapeutic intervention.</p><p>Common high-risk procedures (bleeding risk ≥1 percent in the general population) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Esophagogastroduodenoscopy (EGD) with esophageal variceal ligation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EGD with esophageal dilation </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous endoscopic gastrostomy tube placement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy with polypectomy of polyp ≥1 cm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ERCP with biliary or pancreatic sphincterotomy</p><p></p><p>Common low-risk procedures (bleeding risk &lt;1 percent in the general population) include  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Upper gastrointestinal endoscopy (esophagogastroduodenoscopy) including mucosal biopsy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy including mucosal biopsy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic retrograde cholangiopancreatography (ERCP) without sphincterotomy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ERCP with biliary stent placement</p><p></p><p>The approach to managing patients with disorders of hemostasis depends in part on whether the procedure is high or low risk for bleeding. In addition, for some procedures (ie, screening colonoscopy), the preprocedure estimate of bleeding risk is uncertain because it is unknown whether a high-risk intervention (ie, removal of polyp ≥1 cm) will be necessary. </p><p class="headingAnchor" id="H3583159731"><span class="h2">Specialty consultation</span><span class="headingEndMark"> — </span>We consult with the clinician(s) managing the patient's underlying disorder of hemostasis (eg, hematologist, hemophilia treatment center) to estimate the patient's bleeding risk and to guide periprocedural management.</p><p class="headingAnchor" id="H15"><span class="h1">INHERITED DISORDERS</span></p><p class="headingAnchor" id="H3300707227"><span class="h2">Urgent procedures for gastrointestinal bleeding</span><span class="headingEndMark"> — </span>Patients with inherited disorders of hemostasis who have active gastrointestinal (GI) bleeding are managed similarly to patients with active bleeding from non-GI sources, and these issues are addressed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>von Willebrand disease (VWD) – (See  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery", section on 'Overview of approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemophilia A and B – (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Acute therapy for bleeding'</a>.)</p><p></p><p class="headingAnchor" id="H3712519552"><span class="h2">Nonurgent endoscopy</span><span class="headingEndMark"> — </span>Inherited disorders of hemostasis may increase the risk of spontaneous and intervention-related bleeding from nonurgent or elective endoscopy and often require pre- and postprocedure therapy. (See <a class="local">'von Willebrand disease'</a> below and <a class="local">'Hemophilia A and B'</a> below.) </p><p>Outcome data for bleeding prophylaxis in patients with inherited disorders are limited, while collaboration with a hematologist or hemophilia treatment center (HTC) is an important aspect of care [<a href="#rid1">1-3</a>]. In a retrospective review that included 48 individuals with VWD, hemophilia, or other inherited factor deficiencies who underwent 104 endoscopic procedures under the guidance of a HTC, the overall bleeding rate at 72 hours was 1 percent [<a href="#rid1">1</a>]. One patient with hemophilia A developed postpolypectomy bleeding (1 of 21 polypectomies [5 percent]). For comparison, studies on colonoscopy in anticoagulated patients report postpolypectomy bleeding rates ranging from &lt;1 to 12 percent [<a href="#rid4">4-7</a>]. (See  <a class="medical medical_review" href="/d/html/2671.html" rel="external">"Management and prevention of bleeding after colonoscopy with polypectomy", section on 'Measures to prevent bleeding'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">von Willebrand disease</span><span class="headingEndMark"> — </span>VWD is the most common inherited bleeding disorder, with an estimated prevalence in the general population of 0.1 percent [<a href="#rid8">8</a>]. Acquired von Willebrand syndrome can be seen in individuals with reduced production or increased destruction of von Willebrand factor (VWF), which may occur with certain myeloproliferative neoplasms, aortic stenosis, hypothyroidism, or other disorders. (See  <a class="medical medical_review" href="/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease"</a> and  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a>.)</p><p>VWF performs two critical functions in hemostasis: it acts as a bridging molecule for normal platelet adhesion to collagen and platelets, and it acts as a carrier for factor VIII in the circulation, increasing the half-life of factor VIII fivefold [<a href="#rid9">9</a>]. </p><p>Three types of VWD have been recognized [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 is the most common form and is due to reduced levels of functional VWF</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 2 is due to dysfunctional VWF that has defective interactions with platelets or collagen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 3 is caused by absent VWF</p><p></p><p>Periprocedural management depends upon the type and severity of VWD and the bleeding risk of the procedure. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with mild type 1 VWD who are undergoing diagnostic upper endoscopy (without mucosal biopsy) and have previously demonstrated a response to DDAVP (<a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>) may be treated with DDAVP before the procedure to reduce the risk of bleeding [<a href="#rid11">11</a>]. DDAVP causes release of endogenous VWF from platelets and endothelial cells. (See  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with more severe disease (eg, type 3 VWD) or for those in whom DDAVP is not effective  (<a class="graphic graphic_table graphicRef71525" href="/d/graphic/71525.html" rel="external">table 2</a>), VWF concentrates may be administered. (See  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery", section on 'VWF concentrates for major bleeding'</a>.)</p><p></p><p>Evidence to guide decision-making for patients undergoing a high-risk procedure (colonoscopy with polypectomy, biliary sphincterotomy) is limited [<a href="#rid4">4,11</a>]. Management of patients with VWD who require procedural or surgical intervention is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery"</a>.) </p><p class="headingAnchor" id="H17"><span class="h3">Hemophilia A and B</span><span class="headingEndMark"> — </span>Hemophilia A (inherited factor VIII deficiency) and hemophilia B (inherited factor IX deficiency) are X-linked disorders that mainly affect males, although some female carriers can also have a mild bleeding disorder. </p><p>Periprocedural management depends on which factor is deficient, the baseline factor level (disease severity), and whether an inhibitor (an autoantibody against infused factor) is present [<a href="#rid12">12,13</a>]. Individuals with severe disease (factor activity level &lt;1 percent) and moderate disease (factor activity level 1 to 5 percent) generally are treated with factor infusions. Those with mild hemophilia A (factor VIII activity level 5 to 40 percent) can sometimes be treated with DDAVP for low bleeding risk procedures; DDAVP causes release of endogenous factor VIII from endothelial cells. Details of factor administration and other options for individuals with hemophilia who are undergoing procedural intervention are presented separately. (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">ACQUIRED DISORDERS</span></p><p class="headingAnchor" id="H20"><span class="h2">Cirrhosis</span><span class="headingEndMark"> — </span>Patients with cirrhosis have a variety of hemostatic abnormalities that may increase the risk of bleeding (as well as thrombosis) because impaired hepatic function leads to both procoagulant and anticoagulant effects [<a href="#rid14">14</a>]. Hepatic dysfunction may result in coagulation factor defects in addition to thrombocytopenia and platelet dysfunction. </p><p>The approach to managing patients with cirrhosis who are undergoing gastrointestinal (GI) endoscopy depends on whether there is active GI bleeding and the procedure-related bleeding risk. Other important considerations include minimizing portal pressure in individuals with varices and optimizing hemostatic parameters and renal and hepatic function when possible. Details of this approach are presented separately: </p><p class="bulletIndent1"><span class="glyph">●</span>Active bleeding – (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'General approach to managing bleeding'</a> and  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding", section on 'Blood products'</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonurgent procedure – (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Immune thrombocytopenia (ITP) or other causes of thrombocytopenia</span><span class="headingEndMark"> — </span>Immune thrombocytopenia (ITP; due to an acquired autoantibody) is one of the most common causes of acquired thrombocytopenia. Other causes may include sepsis, infection, and/or medications (ie, drug-induced thrombocytopenia). (See  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a> and  <a class="medical medical_review" href="/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p>Patients with active bleeding and a low platelet count (eg, &lt;50,000/microL) are transfused with platelets. The management of patients with thrombocytopenia who are actively bleeding and require urgent endoscopy is discussed separately. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'Thrombocytopenia'</a> and  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Actively bleeding patient'</a>.)</p><p>Management of patients with thrombocytopenia undergoing nonurgent procedures depends on the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of thrombocytopenia</strong> – The typical platelet count threshold depends on the procedure-related bleeding risk. (See <a class="local">'Estimating procedure-related bleeding risk'</a> above and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults", section on 'General management principles'</a>.). </p><p></p><p class="bulletIndent1">Commonly used platelet count thresholds are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High bleeding risk procedure – 50,000/microL [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low bleeding risk procedure – 20,000/microL.</p><p></p><p class="bulletIndent1">Data on postprocedure bleeding in patients with thrombocytopenia are limited. In an retrospective review of 395 patients with platelet counts ≤75,000/microL (most patients had platelet count ≤50,000/microL) who underwent 617 endoscopic procedures, the postprocedure bleeding rates were 1.5 percent (6 of 398) after mucosal biopsy and 4 percent (2 of 45) after polypectomy [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology of thrombocytopenia</strong> – For some patients, the underlying condition responsible for a patient's thrombocytopenia may determine the bleeding risk and subsequent therapy. For example, patients with ITP who are scheduled for elective endoscopy may be given glucocorticoids or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> to increase the platelet count; the timing of and approach to using these treatments is discussed separately. (See  <a class="medical medical_review" href="/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other risk factors</strong> – For some patients with thrombocytopenia, other risk factors for bleeding inform the decision to transfuse platelets (eg, age &gt;65 years, prior history of bleeding, medication use [eg, anticoagulants, antiplatelet agents]). For example, we give platelet transfusion prior to any endoscopic procedure for patients with platelet counts &lt;50,000/microL who are taking anticoagulants or antiplatelet agents and who have a prior history of bleeding [<a href="#rid17">17</a>]. Management of anticoagulants and antiplatelet agents in patients undergoing endoscopic procedures is discussed separately. (See  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a>.)</p><p></p><p class="headingAnchor" id="H2689018249"><span class="h2">Severe renal dysfunction</span><span class="headingEndMark"> — </span>Patients with severe renal dysfunction (ie, severely impaired glomerular filtration rate) and uremia have increased bleeding risk due to the effects of uremia on platelet function [<a href="#rid18">18</a>]. Management of such patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction"</a>.)</p><p class="headingAnchor" id="H3732252847"><span class="h2">Disseminated intravascular coagulation</span><span class="headingEndMark"> — </span>Disseminated intravascular coagulation (DIC) can cause bleeding or thrombosis. Management of bleeding is primarily directed at treating the underlying cause of DIC. Additional interventions may be appropriate to reduce bleeding risk during endoscopic or other invasive procedures, as discussed separately. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Prevention/treatment of bleeding'</a>.)</p><p class="headingAnchor" id="H3961584978"><span class="h2">Acquired factor inhibitors</span><span class="headingEndMark"> — </span>Acquired factor inhibitors are autoantibodies to endogenous clotting factors (often directed against factor VIII) that may arise in the setting of pregnancy, malignancy, or other conditions. These can cause severe bleeding and may be especially challenging to manage. Options for reducing bleeding risk and treatment of the autoantibody are discussed separately. (See  <a class="medical medical_review" href="/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)", section on 'Control bleeding'</a>.)</p><p class="headingAnchor" id="H3647529539"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120175.html" rel="external">"Society guideline links: Endoscopy preparation, sedation, and special considerations"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles –</strong> The management of patients with disorders of hemostasis who are undergoing gastrointestinal (GI) endoscopy takes into consideration the disease severity, the procedure-related bleeding risk, and the timing of the procedure (eg, urgent, elective). The bleeding risk also depends on the patient's underlying disorder and the availability of interventions to enhance hemostasis (eg, factor replacement for hemophilia, platelet transfusions for thrombocytopenia). (See <a class="local">'Factors that guide decision-making'</a> above.)</p><p></p><p class="bulletIndent1">We consult with the clinician(s) managing the patient's underlying disorder of hemostasis (eg, hematologist, hemophilia treatment center) to estimate the patient's bleeding risk and to guide periprocedural management. (See <a class="local">'Specialty consultation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urgent procedures for gastrointestinal bleeding <strong>–</strong> For patients with an inherited disorder of hemostasis and active GI bleeding, management is similar to patients with active bleeding from non-GI sources, and these issues are addressed separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>von Willebrand disease (VWD) – (See  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery"</a> and  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hemophilia A and B – (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Acute therapy for bleeding'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonurgent procedures</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with von Willebrand disease, periprocedural management depends upon the type and severity of the disease and the bleeding risk of the procedure. For example, some patients with mild type 1 VWD who are undergoing diagnostic upper endoscopy and have previously demonstrated a response to DDAVP (<a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>) may be treated with DDAVP before the procedure to reduce the risk of bleeding. (See <a class="local">'von Willebrand disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with hemophilia A or B, periprocedural management depends on which factor is deficient, the baseline factor level (disease severity), and whether an inhibitor (an autoantibody against infused factor) is present. Details of factor administration and other options for individuals with hemophilia who are undergoing procedural intervention are presented separately. (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia –</strong> For patients with thrombocytopenia undergoing endoscopy, the typical platelet count threshold depends on the procedure-related bleeding risk (see <a class="local">'Estimating procedure-related bleeding risk'</a> above); commonly used platelet count thresholds are (see <a class="local">'Immune thrombocytopenia (ITP) or other causes of thrombocytopenia'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High bleeding risk procedure: 50,000/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low bleeding risk procedure: 20,000/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of anticoagulants and antiplatelet agents –</strong> The periprocedural management for endoscopic procedures for patients taking anticoagulants or antiplatelet agents is discussed separately. (See  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tomaszewski M, Bienz M, Kherad O, et al. Low endoscopy bleeding risk in patients with congenital bleeding disorders. Haemophilia 2019; 25:289.</a></li><li><a class="nounderline abstract_t">Tintillier V, Branche J, Maunoury V, et al. Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure. Haemophilia 2013; 19:e296.</a></li><li><a class="nounderline abstract_t">Azer SM, Eckerman AL, Rodriguez V, et al. Hemostatic prophylaxis and colonoscopy outcomes for patients with bleeding disorders: A retrospective cohort study and review of the literature. Haemophilia 2020; 26:257.</a></li><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3.</a></li><li><a class="nounderline abstract_t">Kim JH, Lee HJ, Ahn JW, et al. Risk factors for delayed post-polypectomy hemorrhage: a case-control study. J Gastroenterol Hepatol 2013; 28:645.</a></li><li><a class="nounderline abstract_t">Takeuchi Y, Mabe K, Shimodate Y, et al. Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. Ann Intern Med 2019; 171:229.</a></li><li><a class="nounderline abstract_t">Horiuchi A, Nakayama Y, Kajiyama M, et al. Removal of small colorectal polyps in anticoagulated patients: a prospective randomized comparison of cold snare and conventional polypectomy. Gastrointest Endosc 2014; 79:417.</a></li><li><a class="nounderline abstract_t">Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160.</a></li><li><a class="nounderline abstract_t">Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.</a></li><li><a class="nounderline abstract_t">Van Os EC, Kamath PS, Gostout CJ, Heit JA. Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations. Gastrointest Endosc 1999; 50:536.</a></li><li><a class="nounderline abstract_t">Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171.</a></li><li><a class="nounderline abstract_t">Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19:e1.</a></li><li><a class="nounderline abstract_t">Ishizu Y, Ishigami M, Suzuki N, et al. Endoscopic treatment of esophageal varices in hemophiliac patients with liver cirrhosis. Gastrointest Endosc 2015; 81:1059.</a></li><li><a class="nounderline abstract_t">McMurry HS, Jou J, Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur J Haematol 2021; 107:383.</a></li><li><a class="nounderline abstract_t">Simonetto DA, Singal AK, Garcia-Tsao G, et al. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol 2020; 115:18.</a></li><li><a class="nounderline abstract_t">Krishna SG, Rao BB, Thirumurthi S, et al. Safety of endoscopic interventions in patients with thrombocytopenia. Gastrointest Endosc 2014; 80:425.</a></li><li><a class="nounderline abstract_t">Cooper N, Ghanima W. Immune Thrombocytopenia. N Engl J Med 2019; 381:945.</a></li><li><a class="nounderline abstract_t">Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014; 29:29.</a></li></ol></div><div id="topicVersionRevision">Topic 2553 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30748066" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Low endoscopy bleeding risk in patients with congenital bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23672809" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32141697" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hemostatic prophylaxis and colonoscopy outcomes for patients with bleeding disorders: A retrospective cohort study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26621548" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The management of antithrombotic agents for patients undergoing GI endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369027" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors for delayed post-polypectomy hemorrhage: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31307055" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125514" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Removal of small colorectal polyps in anticoagulated patients: a prospective randomized comparison of cold snare and conventional polypectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959685" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact, diagnosis and treatment of von Willebrand disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3936044" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502177" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315614" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22776238" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guidelines for the management of hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25805492" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Endoscopic treatment of esophageal varices in hemophiliac patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34258797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The hemostatic and thrombotic complications of liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895720" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24721520" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety of endoscopic interventions in patients with thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31483965" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Immune Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132242" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Haemostasis in chronic kidney disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
